Balversa (erdafitinib) Disease Interactions
There are 3 disease interactions with Balversa (erdafitinib):
Erdafitinib (applies to Balversa) hyperphosphatemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Phosphate Imbalance
Increases in phosphate levels are a pharmacodynamic effect of erdafitinib. Hyperphosphatemia was reported as adverse reaction in 76% of patients after initiating treatment, with 32% requiring phosphate binders during treatment. Caution and monitoring of phosphate levels is advised in all patients, especially in those at risk or hyperphosphatemia. Follow the manufacturer's dose modification guidelines if required.
Erdafitinib (applies to Balversa) ocular disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Retinal Disorder
Erdafitinib can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect. Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography. Caution and close monitoring is advised in patients with retinal disorders. Follow manufacturers dose modification guidelines in patients at risk or with ocular adverse reactions.
Erdafitinib (applies to Balversa) severe hepatic/renal
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease
The pharmacokinetics of erdafitinib in patients with severe renal impairment, renal impairment requiring dialysis, moderate or severe hepatic impairment is unknown. Caution is advised if used in these patients.
Balversa (erdafitinib) drug interactions
There are 206 drug interactions with Balversa (erdafitinib)
More about Balversa (erdafitinib)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Imprints, Shape & Color Data
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: multikinase inhibitors
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.